109Recent studies have shown that allogeneic MSCs can perform better
immunomodulation than autologous MSCs. These results triggered the use of allo-
geneic MSCs in clinical applications. Commercialized MSC-based products have
been developed and approved as stem cell drugs in some countries (Table 6.2 ).
Osteocel (NuVasive), Trinity (Orthofi x), and LiquidGen (Skye Orthobiologics) use
allogeneic MSCs as the main component for bone regeneration and reduction of
infl ammation. MSC-based products have also been approved in Canada and Korea
for certain diseases. Cartistem is stem cell drug containing umbilical cord blood-
derived MSCs, which was approved in Korea as a drug for osteoarthritis. In 2012,
Prochymal (Osiris Therapeutics), an allogeneic MSC-based product, was approved
in Canada for graft-versus-host disease treatment. To date (2015), there are nine
commercialized MSC-based products approved worldwide. Interestingly, most of
them are allogeneic MSC-based products (Table 6.2 ).
Although MSCs are widely used in clinical treatments, there still are some issues
related to the quality and safety of MSCs (Fig. 6.2 ). To maintain MSC quality and
reduce the risks after MSC transplantation, MSCs should be produced in accor-
dance with good manufacturing practice (GMP) guidelines.
Table 6.2 MSC products approved for clinical use
Names of
productsComponent
of stem
cells IndicationsKind of
transplan
tation Company Country
Cartistem MSCs from
UCBOA Allo Medipost KoreaMPC MSCs N/A Allo Mesoblast Australia
Cupistem MSCs from
ATFistulizing
Crohn’s
diseaseAuto Anterogen KoreaProchymal MSCs from
BMGVHD Allo Osiris
TherapeuticsCanadaAlloStem MSCs from
BMOA Allo AlloSource AmericaHearticellgram-
AMIMSCs from
BMAcute
myocardial
infarctionAuto FCB
PharmicellKoreaOsteocel Plus MSCs from
BMOA Allo NuVasive AmericaTrinity Evolution MSCs from
BMOA Allo Orthofi x AmericaCardioRel MSCs from
BMAcute
myocardial
infarctionAuto Reliance Life
SciencesIndiaMSCs mesenchymal stem cells, BM bone marrow, UCB umbilical cord blood, Auto autologous,
Allo allogeneic, OA osteoarthritis
6 Production of Clinical-Grade Mesenchymal Stem Cells